Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)

This study has been completed.
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Information provided by:
Palatin Technologies Identifier:
First received: January 18, 2007
Last updated: February 22, 2011
Last verified: February 2011
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: May 2007
  Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)